Discover more about the psychedelic industry and Entheon’s pathway by watching and reading our talks, presentations and interviews.

Articles & Podcasts

Benzinga PSYCHED
February 7, 2022

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins

Read Now
February 3, 2022

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

Read Now
January 28, 2022

Report: Psychedelic Drugs Market Report: Trends, Forecast and Competitive Analysis By 2028

Read Now
December 13, 2021

Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments

Read Now
December 3, 2021

Eric Sprott Announces Holdings in Entheon Biomedical Corp.

Read Now
Proactive Investors
November 26, 2021

Entheon Biomedical: Data and DMT among the keys to creating safe and effective treatments for patients battling addiction

Read Now


Daily Mushroom + Entheon Biomedical Mental Health Town Hall
The Dales Report - Unlocking The Potential Of DMT
Benzinga Global Small Cap Conference- December 2021
Benzinga Healthcare Small Cap Conference - September 2021

Speak with Investor Relations

Please enter your information to receive our investor package or reach out to us directly using the information below.

Joseph Cullen
Investor Relations
+1 (778) 919-8615

Please remember our office hours are in Pacific Time (GMT-8, Vancouver - BC, Canada)
By submitting this form you agree to receive communications from Entheon Biomedical. We commit to never selling your data and to keep your information safe. Read our Privacy Policy.
Thank you!
We will contact you soon.
Oops! Something went wrong while submitting the form.